Compare GSK plc (GSK) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Wix.Com Ltd — how do they compare? GSK plc trades at $52.6 (market cap $101.34B), while Wix.Com Ltd trades at $52.37 (market cap $2.23B). The key difference: GSK plc is far larger — about 45.4× Wix.Com Ltd's market cap, and GSK plc pays a 3.49% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| GSK | WIX | |
|---|---|---|
Market Cap | $101.34B | $2.23B |
Sector | Health | Technology |
52-Week High | $61.18 | $184.24 |
52-Week Low | $36.20 | $40.43 |
Enterprise Value | $121.95B | $1.79B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Wix stock trades at $53.13, up 0.8% on the day, amid mixed signals. The technical outlook is bullish with support at $52 and resistance at $54. Fundamentally, revenue grew to $1.99B in 2025, but net income margin remains negative at -1.97%. Recent Q1 2026 earnings missed expectations, contributing to a 56% stock decline in H1 2026. Analyst consensus is strongly bullish with a $83.13 price target, though legal investigations and AI demand concerns create headwinds.
The outlook hinges on execution amid competitive and operational risks. Upside potential exists if Wix leverages AI tools and partnership growth, but investors face volatility from expense spikes and legal scrutiny. The high P/E of 62.84 suggests growth expectations must materialize to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
